Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q2 2025 Earnings Conference Call November 5, 2024 9:00 AM ET Company Participants Richa Periwal - Head of Investor Relations MV Narasimham - Chief Financial Officer Erez Israeli - Chief Executive Officer Conference Call Participants Kunal Dhamesha - Macquarie Neha Manpuria - Bank of America Amey Chalke - JM Financial Mikaela Franceschina - Barclays Harith Ahmad - Avendus Spark Damayanti Kerai - HSBC Bino Pathiparampil - Elara Capital Surya Patra - PhillipCapital Tarang Agarwal - Old Bridge Kunal Randeria - Axis Capital Anubhav Agarwal - UBS Vishal Manchanda - Systematix Operator Ladies and gentlemen, good day, and welcome to the Quarter Two FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participants' lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes.
Here's Why Doctor Reddy's (RDY) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Dr. Reddy's (RDY), Kainomyx Sign Potential Deal for Malaria Drug
Dr. Reddy's (RDY) is gearing up to potentially collaborate with Kainomyx to jointly develop an affordable anti-malarial drug.
Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy
Dr. Reddy's Laboratories stock has risen 29% since my last publication, with additional tailwinds from legislative changes and strong business momentum. The company's enduring competitive advantage as a generics pharmaceutical manufacturer produces abnormally high and persistent returns on capital. Quarterly insights show growth in U.S. generics, Europe, and India markets, with high-quality economic characteristics supporting $107/share intrinsic value.
Dr. Reddy's (RDY) Q1 Earnings Miss Estimates, Revenues Beat
Dr. Reddy's (RDY) reports mixed first-quarter fiscal 2025 results, wherein earnings lag estimates, but revenues beat the same, driven by growth in global generics sales in North America and India.
Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug
Dr. Reddy's (RDY) is set to acquire Haleon's leading global NRT brand, Nicotinell, and its related portfolio across all formats of the drug for GBP 500 million to boost its OTC presence worldwide.
Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar
Dr. Reddy's (RDY) announces entering into a license and supply agreement with Alvotech to develop and commercialize the latter's biosimilar candidate, AVT03, to Prolia and Xgeva.
